How The NIH Maximizes Covid Hospitalizations By Not Recommending Anti-Inflammatories

Last Updated on August 17, 2022 by Shaun Snapp

Executive Summary

  • The US NIH developed a deadly covid treatment protocol that is guaranteed to maximize hospitalizations.
  • We explain the illogic of this protocol.


In the article How the US Covid Treatment Protocol Maximized Hospital Admissions and Deaths, I covered the overall impact of the protocol. This article deals with the subtopic of why the NIH does not recommend anti-inflammatories for covid before hospitalization. Even though it is well known, this is one of the most important things to give patients.

Our References for This Article

If you want to see our references for this article and related Brightwork articles, visit this link.

The Deadly Covid Treatment Protocol Designed by the NIH

Now that we have covered Remdesivir, the title of this article, the covid treatment protocol.

Here is the protocol for treating covid by stage.

First Stage

Before a patient is hospitalized, there no treatment is recommended. There are many effective treatments for covid, but the NIH did not recommend any of these be used for some strange reason.

The impact of this treatment will be to maximize the number of patients that end up being admitted to the hospital for covid treatment.

Second Stage

After hospitalization, oxygen, Remdesivir, and Dexamethasone are recommended. Dexamethasone is an anti-inflammatory and, surprisingly, is off-patent—the WHO has the following to say about Dexamethasone.

Dexamethasone is off-patent and has been marketed in different formulations (e.g., tablets, liquid, solution for injection) for many years. It is generally available in most countries. There are several manufacturers of the product. One manufacturer has already been prequalified by WHO (Kern Pharma in Spain) while another is under assessment.

According to preliminary findings shared with WHO (and now available as a preprint), for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.

When this protocol was selected, the WHO did not have any published findings but worked off of the preliminary conclusions. The problem with preliminary findings is that they tend not to match the findings when the study is published. Dr. Fauci has repeatedly used initial findings to obtain Emergency Use Authorization before anyone can review the actual studies.

Third Stage

The third stage is a continued combination of oxygen and Remdesivir and Dexamethasone. But here, high flow oxygen is recommended.

Fourth Stage

The fourth stage is a combination of intubation and a ventilator and Remdesivir and Dexamethasone.

Before we get into the topic of ventilation, one might ask where monoclonal antibodies are in the covid treatment protocol? The FDA approved monoclonal antibodies for treating covid but have been essentially blocked from use, and I will cover this topic further in the article.

This video covers how monoclonal antibodies (MAs) have been suppressed by medical authorities even though they have been proven effective. 

And after having MAs “hypothetically” approved, the FDA came out on Jan 25, 2022, and completely banned them as is explained in the following quotation.

“Because data show these treatments are highly unlikely to be active against the Omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time,” the FDA stated. “In the future, if patients in certain geographic regions are likely to be infected or exposed to a variant that is susceptible to these treatments, then use of these treatments may be authorized in these regions.”

The FDA, citing a National Institutes of Health panel, which in turn cited two non-peer reviewed papers, said two of the monoclonal antibody treatments do not work against Omicron, a recently-emerged variant of the virus. – The Epoch Times

Most likely this study was rigged by the NIH to make it appear as if MAs are not effective. Fauci has a large number of testing companies that will show whatever Fauci wants shown. Fauci tells them the outcome, and the entity provides the desired result.

Why Is No Pre-Hospitalization Anti Inflammatory Recommended to Patients?

Something else that should strike anyone who understands this topic is that covid causes inflammation. However, while Dexamethasone is an anti-inflammatory, and tons of non-drug anti-inflammatories are available, no anti-inflammatory is recommended as part of the protocol before being hospitalized. So let us review what this logic then says.

  • It is essential to take an anti-inflammatory when hospitalized.
  • But there is no reason to take an anti-inflammatory while one has covid but is not yet hospitalized.

Why does one have to wait to be hospitalized for US health authorities to recommend an anti-inflammatory?

Taking anti-inflammatory or even multi anti-inflammatories, in addition to strengthening the immune system, which can also be done outside of the hospital, will help keep people from being hospitalized in the first place. Furthermore, there are many anti-inflammatories that have no side effects and are better for the body in general. This means that there are no negative side effects to recommending many anti-inflammatories.

The success of Anti Inflammatory Treatment Internationally

The US medical establishment does not want the public to know that outpatient anti-inflammatories have been used with great success against covid internationally. This is explained in the following quotations.

Dr. Fernando Valerio, a former Dartmouth trainee who came to national prominence in Honduras for pioneering inpatient and outpatient protocols eventually implemented nationwide. As one of only four intensive-care doctors in San Pedro Sula, a city of 1.2 million, he quickly ruled out a hospitalization-heavy approach as impractical. Instead, he prodded the government to send medical providers door-to-door in virus hotspots to distribute at-home drug kits. And Honduras’ mortality rate declined markedly–to roughly half that of the United States at current count.

Dr. Darrell DeMello in Mumbai, India, who has treated patients, including employees of some of the world’s largest multinational firms, with a drug regimen similar to Dr. Fareed’s, and with similar results. Out of an estimated 7,500 patients, he reports, he has lost 16.

Their work raises hard questions about what the responsible practice of medicine should look like when there are no approved medical treatments in the face of likely widespread death. Could there have been more and earlier life-saving innovation before the pharmaceutical industry’s remarkable development much later of vaccines and novel therapeutics? Is trying something better than doing nothing until lengthy clinical trials are completed? Or, especially when the risks of “fake news” and its viral spread are high, do the demands of providing authoritatively endorsed treatments override all?

Honduras, India, Peru, and Mexico were among the countries that achieved promising results by combining cheap and widely available medicines long proven safe in treating other medical conditions. These included HCQ; azithromycin (AZM, an antibiotic sold under the brand name Zithromax with antiviral and anti-inflammatory properties); doxycycline (used to treat a variety of bacterial infections, and also with antiviral and anti-inflammatory properties); steroids; Tylenol; aspirin and the supplements Vitamins C, D, and zinc.

Most of these regimens also included ivermectin (IVM), a common drug that became increasingly controversial in the U.S. after the podcaster Joe Rogan said his doctor prescribed it off-label to him once he contracted COVID as part of a larger drug cocktail.

In India’s most populous state, Uttar Pradesh, COVID cases and deaths declined rapidly with the implementation of door-to-door visits, during which infected patients were given kits including IVM and doxycycline.

While Dr. DeMello is most emphatic about the importance of colchicine, he also typically prescribes IVM, and the blood thinner Plavix, since COVID also “is a clotting disease.” The idea is to address what in his view are the three pillars of the illness: inflammation, viral replication, and coagulation. – The Epoch Times

However, the NIH completed a study that stated the following.

Multiple randomized trials indicate that systemic corticosteroid therapy improves clinical outcomes and reduces mortality in hospitalized patients with COVID-19 who require supplemental oxygen,1 presumably by mitigating the COVID-19-induced systemic inflammatory response that can lead to lung injury and multisystem organ dysfunction. There is no observed benefit of systemic corticosteroids in hospitalized patients with COVID-19 who do not require supplemental oxygen.2

There are no data to support the use of systemic corticosteroids in nonhospitalized patients with COVID-19. Therefore, the safety and efficacy of systemic corticosteroids in this population have not been established. – NIH

This contradicts all of the evidence that has come around from the field around the world, which is far more critical than any clinical trial. In this case, it appears the NIH rigged to make it appear that anti-inflammatories do not work against covid unless hospitalized. The claims made in the NIH study are so ridiculous that it is incredible to read. Why would anti-inflammatories only work with oxygen?

Another NIH study provides information that was already known without the NIH pointing this out.

Melatonin is a naturally occurring sleep hormone with antiinflammatory and antioxidative effects, whose production wanes with aging.9 Melatonin has long been available as a nonprescription sleep aid and has previously been studied for its anti-lung injury effects in viral illnesses. A large observational study from the Cleveland Clinic (N = 26,779 individuals from a COVID-19 registry) indicated that those taking melatonin had a 28% reduced risk in infection from SARS-CoV-2.26 Melatonin doses of 3 to 10 mg at bedtime are generally regarded as safe in adults, and melatonin is well tolerated with few reported side effects.10 At a minimum, this intervention may improve the quality of sleep, which can support recovery and provide comfort for people who are suffering with COVID-19 symptoms at home.

Finally, vitamin D deficiency appears to be associated with worse outcomes in COVID-19.10 A 6-week prospective observational study showed significantly higher mean vitamin D levels in asymptomatic than in severely ill COVID-19 patients (27.89 ± 6.21 vs 14.35 ± 5.8 ng/mL). Moreover, the prevalence of vitamin D deficiency was 33% in asymptomatic patients vs 97% in critically ill COVID-19 patients. A small pilot randomized clinical trial from Spain showed that 25-hydroxyvitamin D supplementation can significantly reduce the need for ICU care in hospitalized COVID-19 patients.11 While some authors advise widespread supplementation of vitamin D in at-risk populations, we would consider safe supplementation (2000–4000 IU daily) for COVID-19 patients at risk for both vitamin D deficiency and adverse outcomes.

However, notice that neither melatonin nor vitamin D, anti-inflammatories, and immunomodulators is recommended as part o the covid treatment protocol.

This means that patients in Honduras receive superior treatment vis-a-vis covid versus the US.

What The Covid Protocol Does

The outcome of the US covid treatment protocol is to maximize the number of people sent to the hospital, which maximizes revenue to the hospital. This is the “butts in seats” approach to dealing with a pandemic, and it is ridiculous. Medicare backed up this protocol with financial incentives.

  • Hospitals were paid roughly $13,000 for each patient admitted for treatment and tested positive for covid.
  • Hospitals were paid roughly $40,000 for each patient placed on a ventilator. The hitch is they must stay on the ventilator for 96 hours.

The financial incentives to place people on ventilators are covered in more detail in the article Were Covid Patients Put on Ventilators to Maximize Hospital Profits? 

What is curious is that the NIH, FDA, and CDC are providing a protocol that is not focused on the interests of the covid patients.


The only conclusion that makes sense to us for not making anti-inflammatories part of the covid protocol is that the NIH wanted to maximize hospitalizations. This maximizes revenues to hospitals and to Gilead Sciences, which makes Remdesivir.